Modulation of GYS1 expression
AssigneesIonis Pharmaceuticals, Inc., The Hospital for Sick Children
InventorsTamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
Claims17
A method of treating Lafora disease in an individual having Lafora disease comprising administering to the individual a compound comprising a modified oligonucleotide consisting of 15 to 30 nucleosides, wherein the modified oligonucleotide has a nucleobase sequence at least 95% complementary to an equal length portion of the nucleobase sequence of any one of SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, or SEQ ID NO:
- 5, wherein at least one internucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage, and wherein Lafora bodies are reduced in a cell in the individual, thereby treating the Lafora disease in the individual.
Dependencies are inferred from the claim text.